The “norm and practice” of Pharmaceutical companies is to vehemently deny the most serious adverse side effects of their products. This industry’s success in concealing the truth about the serious harm caused by their drugs and vaccines has been aided and abetted . . . Continue reading →
Part II. What Do We Get for All That Money? A preventable epidemic of injury and death from prescription drugs; FDA’s contribution to the epidemic; Big Pharma’s business model: manufactured myths, propaganda and a hidden agenda;
The US Court of Appeals, 1st Circuit overturned a summary judgement by a lower court ordering a whistleblower lawsuit filed by Dr. Kenneth Jones against Harvard Medical School, its teaching hospitals, Brigham and Women’s and Massachusetts General Hospital, and Dr. Marilyn Albert (Principal Investigator) and Dr. Ronald Killiany to proceed to trial.
Continue reading →
On Friday, April 6, the FDA approved another of Eli Lilly’s "breakthroughs" whose clinical value is questionable (at best). Continue reading →
The largest private global health foundations exert inordinate influence on public health policy–ensuring that those policies increase profits for their corporate and endowment portfolios. Continue reading →
A meta- analysis of 61 studies in PLoS ONE found an increased risk of breast cancer for women taking an antidepressant. Continue reading →
Johnson & Johnson officilas made a business decision to decieve doctors by lying about the diabetes risk: “how much commercial liability would we incur if we sent a similar letter about Risperdal”? Continue reading →
This year alone, because of patent expirations, the drug industry will lose control over more than 10 megamedicines whose combined annual sales have neared $50 billion.
America’s health care expenditure is about to go through the roof–without improving anyone’s health! Continue reading →
The excerpts from The New Yorker (below) may be read as a companion piece to the Atlantic article profiling Dr. John Ioannidis. However, the opening example that Lehrer uses to make the point that initial impressive positive research findings often weaken . . . Continue reading →
Topical tacrolimus and pimecrolimus: cancer, infections—"a clearly unfavorable benefit-risk ratio"— Prescrire International 2010 ; 19 (110) : 257 English edition.
From 1991-2000 qui tam law suits accounted for only 9% of settlements with the government. But from 2001-2010, qui tam settlements comprised 67% of the billions in payouts Continue reading →